- 1 Plasma biomarker profiles and the correlation with cognitive function across the
- 2 clinical spectrum of Alzheimer's disease
- 4 Zhenxu Xiao^{1,2†}, Xue Wu^{3†}, Wanqing Wu^{1,2}, Jingwei Yi³, Xiaoniu Liang^{1,2}, Saineng
- 5 Ding^{1,2}, Li Zheng^{1,2}, Jianfeng Luo^{4,5}, Hongchen Gu³, Qianhua Zhao^{1,2*}, Hong Xu^{3*},
- 6 Ding Ding^{1,2}

7

- 8 ¹ Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China;
- 9 ² National Clinical Research Center for Aging and Medicine, Huashan Hospital,
- 10 Fudan University, Shanghai, China;
- 11 ³ School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai,
- 12 China:
- 13 ⁴ Department of Biostatistics, School of Public Health, Fudan University, Shanghai,
- 14 *China*;

17

18

19

- 15 ⁵ Key Lab of Public Health Safety of the Ministry of Education, Fudan University,
- 16 Shanghai, China.

- 20 * Correspondence to: Qianhua Zhao, Institute of Neurology, Huashan Hospital, Fudan
- 21 University, 12 Wulumuqi Zhong Rd., Shanghai 200040, China;
- 22 qianhuazhao@fudan.edu.cn
- or Hong Xu, School of Biomedical Engineering, Shanghai Jiao Tong University,
- 24 Shanghai, China; xuhong@sjtu.edu.cn
- 25 † Zhenxu Xiao and Xue Wu contributed equally to this article.

Abstract

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

- **Background** Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer's disease (AD). However, profiles of the biomarkers and the association with cognitive domains along the spectrum of cognitive performance deterioration have seldom been reported. Methods We recruited 320 individuals with cognitive impairment and 131 cognitively normal participants from a memory clinic and a community cohort. Participants were classified into 6 groups based on their Clinical Dementia Rating (CDR) scores and clinical diagnosis of AD, amnestic mild cognitive impairment, and normal cognition (NC). Each participant was administered the neuropsychological tests assessing the global and domain-specific cognition. Plasma $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}$ / $A\beta_{1-40}$, total tau (t-tau), neurofilament protein light chain (NfL), and phosphorylated tau at threonine 181 (p-tau181) were quantified using the Single molecule array platform. **Results** Along with plasma $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}$ / $A\beta_{1-40}$, t-tau, and NfL, p-tau181 significantly increased across the groups with the incremental CDR scores from NC (CDR = 0) to severe AD (CDR = 3). Compared with other biomarkers, p-tau181 had a stronger correlation with Global cognition (r = -0.494, P < 0.001), Memory (r =-0.417, P < 0.001), Attention (r = -0.388, P < 0.001), Visuospatial function (r = -0.328, P < 0.001), and Language (r = -0.123, P = 0.014). Among AD participants with CDR \geq 1, higher p-tau181 was correlated with worse Global cognition (r = -0.295, P <0.001), Memory (r = -0.172, P = 0.045), and Attention (r = -0.184, P = 0.031). **Conclusions** Plasma p-tau181 had a stronger correlation with cognitive domains than other biomarkers, especially in late-stage AD. It could reflect the AD pathology in vivo and may be a promising blood-based biomarker in clinical settings.
- 50 **Key words** Plasma p-tau181, Simoa, cognitive domain, CDR, Alzheimer's disease

Background

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Alzheimer's disease (AD), the most common cause of dementia, is characterized by the accumulation of the amyloid plaques and neuronal tangles in the brain [1]. Previous AD-relevant biomarkers could only be detected in the cerebrospinal fluid (CSF) or through positron emission tomography (PET) [1]. With the development of ultrasensitive immunoassays technique, detecting AD relevant biomarkers in blood samples became available [2]. Plasma biomarkers have a promising value in clinic usage due to the non-invasiveness, cost-effectiveness, and easy accessibility [3]. Following $A\beta_{1-40}$, $A\beta_{1-40}$, total tau (t-tau), neurofilament protein light chain (NfL), recently reported plasma phosphorylated tau at threonine 181 (p-tau181) showed better diagnostic performance and prognostic value in several cohort studies [3-9]. The cognitive performance is a pivotal indicator in AD management and efficacy evaluation. Previous studies found plasma A β_{1-42} [10], NfL [11, 12], and p-tau181 [3, 4, 13] were significantly different in participants with mild cognitive impairment (MCI) and AD compared with participants with normal cognition (NC). However, few studies depicted plasma biomarkers' profiles based on the cognitive performance and compared their discrepancy during the entire course of AD. It would be valuable to depict the trajectory of different plasma AD biomarkers from NC until the severe cognitive impairment stage since the cognitive manifestations are the most concerned issues for both clinicians, patients, and the caregivers. In addition, some studies investigated the relationships between plasma biomarkers and various cognitive domains [14-23]. However, they only focused on individual markers, and the results were incomparable or inconsistent due to the diverse testing platforms and study designs. It is also worthwhile to observe which biomarker has the best correlation with diverse cognitive domains.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

In this study, we aimed to observe the trajectory of the plasma biomarkers profile, including $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}$, $A\beta_{1-40}$, t-tau, NfL, and p-tau181, across the clinical spectrum of AD evaluated with the clinical dementia rating (CDR) scale. We also intended to explore the correlation between these biomarkers and the domain-specific cognitive function, especially in different clinical AD stages. Methods **Study participants** Participants with cognitive impairment were consecutively recruited from the memory clinic of the department of neurology, Huashan Hospital, Shanghai, China from November 2018 to September 2020. The inclusion criteria included: (1) consulted at the memory clinic due to memory complaints from herself (himself) or proxy; (2) able to cooperate with physical examinations and neuropsychological tests; (3) diagnosed with single-domain amnestic MCI (aMCI-s), multi-domain amnestic MCI (aMCI-m), or AD; (4) consent to the blood draw. Participants in the Shanghai Aging Study (SAS) were eligible to be selected as the controls with NC. The SAS is a community-based longitudinal cohort in downtown Shanghai, China. The original purpose of SAS was to investigate the prevalence, incidence and risk factors for dementia and MCI among older residents in an urban community. The detailed study design and recruitment procedure have been published elsewhere [24]. In this study, the participants were selected from the third wave of follow-up between Jun and Oct in 2020 if they were: (1) 60 years or older; (2)

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

able to cooperate with physical examinations and neuropsychological tests; (3) diagnosed with NC; (4) consent to the blood draw. **Demographics and assessment of covariables** The demographic and lifestyle characteristics were acquired from the participants and/or proxy through a questionnaire. The educational background was defined as the years of formal education. Participants who smoked daily within the past month were regarded as cigarette smoking, and participants who had one serving of alcohol weekly during the past year were defined as alcohol consumption [25]. Hypertension and diabetes mellitus were confirmed by the medical records [24]. Apolipoprotein E (APOE) genotype was assessed by the Taqman single nucleotide polymorphism method using the blood or saliva samples collected from the participants [26]. The presence of at least one APOE ε4 allele was regarded as APOE ε4 positive. **Neuropsychological tests** Comprehensive neuropsychological tests were administered by the certified psychometrists. All the tests were translated and adapted from western countries harmonized to Chinese culture, and were validated in Chinese population. Each participant from the memory clinic received a battery of neuropsychological tests, including: (1) Mini-Mental Status Examination (MMSE) [27]; (2) Montreal Cognitive Assessment-Basic (MoCA-B) [28-30]; (3) Auditory Verbal Learning Test [31, 32]; (4)

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Symbol Digit Modalities Test [33, 34]; (5) Rey-Osterrieth Complex Figure test [34]; (6) Boston Naming Test [35]; (7) Trail Making Test (TMT) [36]. For those who refused or were unable to complete the whole battery of tests, only MMSE and MoCA-B were administered. As for the participants with NC, a battery of similar neuropsychological tests was administered [31]: (1) MMSE [27]; (2) Auditory Verbal Learning Test [31, 32]; (3) Conflicting Instructions Task (Go/No-Go Task) [31]; (4) Stick Test [31]; (5) Modified Common Objects Sorting Test [31]; (6) TMT [36]. We extracted raw scores from above-mentioned neuropsychological tests to evaluate five clinically relevant cognitive domains including Memory, Attention, Visuospatial function, Language, and Executive function (Supplementary Table 1). Z-scores (Z = (raw score - mean)/standard deviation) of domains were computerized for analysis. Cognitive impairment severity and consensus diagnosis All participants and their proxy were interviewed by two neurologists specialized in neurodegenerative diseases. The CDR, a semi-structured inventory, was used to assess the severity of cognitive impairment. It covered six cognitive, behavior, and function aspects, including memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The neurologists scored on each aspect, taking into consideration information collected from both participants and proxy. The global CDR score was calculated automatically on biostat.wustl.edu/~adrc/cdrpgm/index.html by inputting in each CDR box score,

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

based on the Washington University CDR-assignment algorithm with a 0-3 scale index [37, 38]. Neurologists and neuropsychologists reached a consensus diagnosis of the cognitive function of each participant. The presence or absence of dementia was defined using the DSM-□ criteria [39]. AD was diagnosed according to the NINCDS-ADRDA criteria [40]. The diagnosis of MCI was based on Petersen's criteria [41]: (1) cognitive complaint by the subject, informant, nurse, or physician, with CDR = 0.5; (2) objective impairment in at least 1 cognitive domain. (3) essentially normal functional activities (determined from the CDR and the Activities of Daily Living evaluation); and (4) absence of dementia [42]. Because aMCI is more likely to progress to AD [43], we only included participants with 2 types of aMCI: (1) aMCI-s, memory impairment was required with no deficit in other domains; (2) aMCI-m, memory impairment plus at least 1 additional deficit in another domain. NC participants had no memory complaint and have been confirmed cognitively intact through detailed neuropsychological assessment. For participants from memory clinic, laboratory tests and MR scan were performed to rule out the secondary causes related to cognitive impairment. In this study, the continuum of AD was described based on the combination of CDR and the cognitive diagnosis: NC (CDR = 0), aMCI-s (CDR = 0.5), aMCI-m (CDR = 0.5), mild AD (CDR = 1), moderate AD (CDR = 2), and severe AD (CDR = 3) [37, 38].

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

Plasma biomarkers measurement Blood samples were collected in Ethylene Diamine Tetraacetic Acid (EDTA) plasma tubes and centrifuged (1,000 rpm, 4 °C) for 15 min. After the centrifugation, plasma was transferred into 1.5ml Eppendorf tubes and stored at −80 □ °C refrigerators. Plasma $A\beta_{1-40}$, $A\beta_{1-42}$, t-tau, NfL, and p-tau181 were quantified using an ultra-sensitive Single molecule array (Simoa) (Quanterix, MA, US) on the automated Simoa HD-X platform per manufacturer's instruction. The multiplex Neurology 3-Plex A kits (Cat. No. 101995), NF-light assay (Cat. No. 103186), and p-tau181 Assay Kit V2 (Cat. No.103714) were purchased from Quanterix and used accordingly. Technicians who performed the assay were blinded to the clinical data. **Statistical Analyses** Mean and standard deviation (SD) were used to describe normally distributed continuous variables, while the median and quartile 1 (Q1) to quartile 3 (Q3) were used to describe the skewed distributed continuous variables. For categorical variables, number (n) and frequencies (%) were employed. One-way Analyses of Variance (ANOVA) and Kruskal-Wallis tests were used for comparing continuous variables, and Pearson Chi-square and Fisher exact tests were used to compare the categorical variables. For the comparisons among multi-groups, ANOVA and post hoc Tukey multiple comparison tests were used for variables with equal variance, while Welch

and post hoc Games-Howell tests were used for variables with unequal variance.

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

Boxplots and points were used to present the distributions of original values of six plasma biomarkers. Levene's tests were used for testing the homogeneity of variances in six groups with different cognition status. Associations between domain-specific Z scores and log-transformed plasma biomarker indexes (due to non-normal distributions [3]) were examined using partial Pearson correlation analyses with the adjustment for confounding variables. The heatmap matrix was implemented to visualize the adjusted partial correlation coefficients r in all participants. Positive correlations (r > 0) were exhibited in red, and negative correlations (r < 0) were exhibited in blue in the heatmap figure. The same correlation analyses were applied to participants with CDR = 0, CDR = 0.5, and CDR \geq 1, respectively. Two-sided $P \square < \square 0.05$ was considered statistically significant. Data were analyzed using IBM SPSS Statistics for Windows, version 25.0 (IBMCorp., Armonk, N.Y., USA) [44] and R (version 4.0.2) [45]. Box plots were produced using the package ggplot2 in R. The heatmap was visualized by GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, California USA (www.graphpad.com). **Results Characteristics of the study participants** We recruited 451 participants, including 320 participants from the memory clinic cohort and 131 NC participants from the community cohort. The characteristics of study participants were shown in Table 1. Significant difference was found in gender (P = 0.011), age (P < 0.001), education years (P < 0.001), and APOE $\varepsilon 4$ allele (P < 0.001)

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

0.001) among six cognitive performance groups. The most severe cognitive-impairment group (CDR = 3) had the highest proportion of women (68.4 %), the lowest mean age (mean = 62.3), the shortest education years (mean = 5.6), and the largest proportion of positive APOE ε 4 allele (57.9 %). We did not find the significant discrepancy in smoking, alcohol consumption, hypertension, and diabetes mellitus among six groups. All Neuropsychological tests' scores were significantly different among six groups (all P < 0.001). Plasma biomarkers across groups with different cognitive performance As shown in Figure 1, plasma $A\beta_{1-40}$, $A\beta_{1-42}$, and $A\beta_{1-42}/A\beta_{1-40}$ ratio showed a descending trend, while plasma t-tau, NfL, and p-tau181 exhibited an increasing trend across groups with the increasing CDR scores in general. With regard to $A\beta_{1-40}$, $A\beta_{1-42}$ and NfL, we found significant differences between participants with NC (CDR = 0) and AD (CDR \geq 1) (Figure 1 A, B and E). A $\beta_{1-42}/A\beta_{1-40}$, and t-tau showed differences only between participants with NC (CDR = 0) and severe AD (CDR = 3) (Figure 1 C and D). There was no significant discrepancy of $A\beta_{1-40}$, $A\beta_{1-42}$, $A\beta_{1-42}$, $A\beta_{1-40}$, t-tau, or NfL among participants with different severity level of AD (CDR = 1, 2, or 3). P-tau181 gradually increased across the AD cognitive continuum, with the lowest concentration in NC participants (CDR = 0), an increase in participants with aMCI (CDR = 0.5), and the highest concentration in participants with AD (CDR \geq 1) (Figure 1 F). Specifically, participants with severe AD (CDR = 3) had significantly higher p-tau181 than those with mild AD (CDR =1). Correlation between plasma biomarkers and domain-specific cognition Figure 2 showed the partial correlation matrix between six plasma biomarkers and

- six domain-specific cognitions after adjusting age, gender, education years, and APOE.
- 235 A β_{1-40} was only correlated positively with Memory (r = 0.125, P = 0.012). A β_{1-42} was
- correlated positively with MMSE (r = 0.119, P = 0.012), Memory (r = 0.203, P < 0.012)
- 237 0.001), and Attention (r = 0.104, P = 0.036), while $A\beta_{1-42}/A\beta_{1-40}$ was correlated
- 238 positively with Memory (r = 0.114, P = 0.022) and Attention (r = 0.100, P = 0.044).
- T-tau had an inverse correlation with MMSE (r = -0.154, P = 0.001), Memory (r =
- -0.146, P = 0.003), and Attention (r = -0.116, P = 0.020). Higher NFL was correlated
- 241 with worse MMSE (r = -0.298, P < 0.001), Memory (r = -0.263, P < 0.001), Attention
- 242 (r = -0.209, P < 0.001), Visuospatial function (r = -0.236, P < 0.001), and Language (r = -0.209, P < 0.001)
- = -0.105, P < 0.036). P-tau181 showed a stronger correlation inversely with MMSE (r
- 244 = -0.497, P < 0.001), Memory (r = -0.417, P < 0.001), Attention (r = -0.388, P < 0.001)
- 245 0.001), Visuospatial function (r = -0.328, P < 0.001), but a weaker correlation with
- 246 Language (r = -0.123, P = 0.014).
- As shown in Table 2, no significant correlation was found between plasma
- biomarkers and cognitive domain scores in NC participants. Among aMCI
- participants with CDR = 0.5, higher $A\beta_{1-42}/A\beta_{1-40}$ was correlated with the
- deterioration of MMSE (r = -0.209, P = 0.011) and Executive function (r = -0.197, P = 0.011)
- = 0.021). Higher NfL was correlated with worse Visuospatial function (r = -0.174, P =
- 252 0.045), and higher p-tau181 was correlated with worse Memory (r = -0.167, P =
- 253 0.048).
- As for the AD participants with CDR ≥ 1 , plasma A β_{1-42} had positive correlation
- only with Memory (r = 0.184, P = 0.030), and $A\beta_{1-42}/A\beta_{1-40}$ had positive correlation
- 256 with MMSE (r = 0.156, P = 0.046) and Attention (r = 0.187, P = 0.028). Increased
- plasma NfL was only correlated with worse Executive function (r = -0.171, P =
- 258 0.048). Higher p-tau181 was correlated with worse MMSE (r = -0.295, P < 0.001),

Memory (r = -0.172, P = 0.045), and Attention (r = -0.184, P = 0.031).

Discussion

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

The present study demonstrated that plasma $A\beta_{1-40}$, $A\beta_{1-42}$, and $A\beta_{1-42}/A\beta_{1-40}$ had a decreasing trend, while plasma t-tau, NfL, and p-tau181 escalated along the deterioration of the cognitive performance. P-tau181 was the best indicator of clinical cognitive performance and had a stronger correlation with global and other cognitive domains than other five AD biomarkers. To our knowledge, it was the first study to exhibit the distribution of plasma p-Tau 181 using the Simoa HD-X platform in Chinese older individuals along the clinical AD continuum. Pathology is pivotal in the diagnosis of AD. However, cognitive performance, including various cognitive domains, played a more significant role in patient management and efficacy evaluation. Cognitive manifestations are closely related to one's daily function and quality of life for both patients and caregivers. Thus, we focused on individual's performance, and classified the participants into six groups according to CDR levels and clinical cognitive diagnosis. One previous study found plasma p-tau181 increased at preclinical AD and further increased at the MCI and dementia stages [3]. Another group verified that plasma p-tau181 gradually increased from the A β -negative cognitively unimpaired older adults, through the A β -positive cognitively unimpaired and MCI groups, to the highest concentrations in Aβ-positive MCI and AD groups [4]. Our results testified their findings from the clinical perspective and further indicated that p-tau181 was a symptom-related plasma biomarker. Although some AD markers showed a significant escalating or descending

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

trend along the whole disease continuum, plasma p-tau181 is the only one that had the significant discrepancy in the later stage of AD with overt dementia symptoms. This means plasma p-tau181 may keep increasing along with the deterioration of cognitive function, till the most severe stage of AD. Previous studies showed that plasma p-tau181 was correlated with CSF p-tau181 in AD patients, suggesting that plasma p-tau181 was originated from the central nervous system [3, 4]. Peripheral p-tau reflects the phosphorylation of the tau protein, which eventually leads to the neurofibrillary tangles in the brain [8]. Therefore, the continuous increment of the plasma p-tau across different stages of AD indicated the ongoing tau-related pathologic change in the brain, even in the late stage of the disease. This may potentially guide the development of disease-modifying therapy for terminal-stage patients in the future. One subset cohort in a study demonstrated that plasma p-tau181 was correlated with baseline MMSE [4]. However, the relationships between plasma p-tau181 and different cognitive domains have not been reported. Our study revealed a strong correlation between plasma p-tau181 and AD-related cognitive domains. The correlations between p-tau181 and MMSE, Memory, and Attention were only observed in participants with dementia symptoms. This phenomenon may mainly reflect the fact that plasma p-tau181 is regulated differently by the disease staging, namely the Alzheimer's pathological status in the brain. Another possibility is that, the narrow range of testing scale weakens the correlation of plasma biomarkers with cognition, due to "ceiling effects" or "floor effects" of the tests. However, this might

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

not be the major explanation, because when analyzing with the more sensitive neuropsychological tests assessing Memory and Attention, the correlations were still not be observed in the subgroup with CDR = 0. The NfL was an age-related biomarker [46]. Lin et. al. found that higher plasma NfL levels correlated with lower MMSE scores [15]. However, they did not adjust for age in the correlation analysis. The results from Chatterjee et. al. showed that plasma NfL was inversely correlated with working memory, executive function, and the global composite score after considering the age [14]. Two studies found plasma NfL associated with all cognitive domains after adjusting potential confounders including age [22, 23]. However, using the same Simoa detecting method, a Chinese group did not find any correlation of NfL with episodic memory, information processing speed, executive function, or visuospatial function after adjusting for age, gender, and education. In our results, the plasma NfL had a significant correlation after adjustment for age and other covariates, not only with global cognition, but also with the other four cognitive domains. This suggested that, although NfL was regarded as a non-specific biomarker for neurological diseases [12], it still has value in the monitoring of AD cognitive deterioration. However, many correlations could not be observed when we classified participants into three groups according to CDR levels of $0, 0.5, \text{ and } \ge 1$. The paradoxical results may reflect the underlying diverse pathophysiological conditions in different cognitive status [46]. The traditional amyloid cascade theory emphasized that $A\beta$ as an initial factor triggers the following Tau pathology [1]. However, the plasma amyloid biomarkers

 $(A\beta_{1-42}, A\beta_{1-40}, A\beta_{1-42}/A\beta_{1-40})$ in our study had a relatively weaker correlation only with MMSE, Memory, and Attention. Previous CSF and PET studies [47, 48] indicated that, the amyloid-related biomarkers reflected the earliest pathological change but tended to reach a plateau as the disease progressed to the dementia stage. Since the plasma A β level was supposed to reflect the central nervous change [49], blood Aß level may also be saturated in the symptomatic individuals. However, in the CDR subgroups, the trend is ambiguous and inconsistent, probably because of the small sample size. Further large-sampled longitudinal studies need to be conducted to demonstrate the dynamic of plasma Aβ levels along the clinical spectrum of AD. A previous experimental study showed that neurons exposed to Aβ had increased synthesis and secretion of tau [50]. These neurons may eventually degenerate and develop tangle pathology, which may also drive the increase of p-tau in the blood. Therefore, regarding AD as a whole disease continuum, plasma p-tau181, as a more sensitive and clinical-relevant blood-based biomarker, may be superior to A\(\beta\).

Limitations

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

There are several limitations in our study. Firstly, the biomarkers in this study were only detected once without longitudinal measurements. However, we separated the participants into six groups according to CDR scores and cognitive diagnosis to simulate the AD spectrum. Future prospective studies are needed to verify our findings. Secondly, the participants in our studies were from two different resources with unavoidable imparity. However, there was no significant difference in some

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

dementia-related risk factors, such as smoking, alcohol consumption, hypertension, and diabetes mellitus (Table 1). Age, gender, education year, and APOE were adjusted in the multivariate statistical models. Thirdly, some neuropsychological tests might have "ceiling effects" (e.g. Go/No-Go Task) or "floor effects" (e.g. Auditory Verbal Learning Test), which may conceal the relationship between the biomarkers and the cognitive domains. Lastly, we diagnosed AD based on the clinical standard rather than pathological evidence of CSF or amyloid/tau PET. Lacking a golden standard impeded us from the classifying of "ATN" framework [51] or Receiver Operating Characteristic analysis. **Conclusions** In conclusion, we found plasma p-tau181 increased along the clinical continuum of AD. Plasma p-tau181 had a stronger correlation with cognitive domains than other biomarkers, especially in late-stage AD. Our study suggests that the plasma p-tau181 could reflect the AD pathology in vivo and may be a promising blood-based biomarker in clinical settings. Longitudinal studies are needed to verify these findings and provide more evidence of the association between plasma p-tau181 and clinical cognitive manifestations. **Abbreviations** AD: Alzheimer's disease; aMCI: amnestic mild cognitive impairment; aMCI-m: amnestic mild cognitive impairment multi-domains; aMCI-s: amnestic mild cognitive

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

impairment single-domain; ANOVA: Analysis of Variance; APOE: Apolipoprotein E; CDR: Clinical Dementia Rating; CSF: cerebrospinal fluid; EDTA: Ethylene Diamine Tetraacetic Acid; MCI: mild cognitive impairment; MMSE: Mini-mental State Examination; MoCA-B: Montreal Cognitive Assessment-Basic; NC: normal cognition; NfL: neurofilament protein light chain; PET: positron emission tomography; p-tau181: phosphorylated tau 181; SAS: Shanghai Aging Study; SD: standard deviation; Simoa: Single molecule array; TMT: Trail Making Test; t-tau: total tau. Acknowledgements Not applicable **Authors' contributions** QZ, HX, and DD developed the original idea. ZX and XW searched the literature. ZX, WW, XL, SD, and LZ collected samples and data. XW and JY measured the blood biomarkers with support from HG. ZX and JL analyzed data. ZX and XW wrote the manuscript. QZ, HX, and DD revised the manuscript. All authors read and approved the final manuscript. **Funding** This work was supported by grants of Clinical Research Plan of SHDC (No. SHDC2020CR4007), Key projects of special development funds for Shanghai Zhangjiang National Innovation Demonstration Zone (201905-XH-CHJ-H25-201),

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

MOE Frontiers Center for Brain Science (JIH2642001/028), Scientific Research Plan Project of Shanghai Science and Technology Committee (17411950106, 17411950701), National Project of Chronic Disease (2016YFC1306402), National Natural Science Foundation of China (82071200, 81773513, 21874091, 31927803), and Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJLab. Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Ethics approval and consent to participate This study was approved by the Medical Ethics Committee of Huashan Hospital, Fudan University, Shanghai, China (No. 2009-195 and 2011-288). All participants and/or their legal proxy gave written informed consent to participate. **Consent for publication** Not applicable **Competing interests** The authors declare that they have no competing interests.

413 **Author details** 414 ¹Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China; 415 ²National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan 416 University, Shanghai, China; ³School of Biomedical Engineering, Shanghai Jiao Tong 417 University, Shanghai, China; ⁴Department of Biostatistics, School of Public Health, 418 Fudan University, Shanghai, China; ⁵Key Lab of Public Health Safety of the Ministry 419 of Education, Fudan University, Shanghai, China. 420 421 References 422 Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. 423 Alzheimer's disease. Lancet (London, England). 2016;388(10043):505-17. 424 2. Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and 425 prospects for the future. J Intern Med. 2018;284(6):643-63. 426 Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma 427 P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, 428 neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 429 2020;26(3):379-86 430 Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood 431 phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance 432 and prediction modelling study using data from four prospective cohorts. The Lancet 433 Neurology. 2020; 19(5):422-33.

Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, Troakes C, King A, Emersic A, et al.

434

435 Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior 436 to post-mortem and improves the clinical characterisation of cognitive decline. Acta 437 Neuropathol. 2020;140(3):267-78. 438 Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, et al. Individualized 439 prognosis of cognitive decline and dementia in mild cognitive impairment based on 440 plasma biomarker combinations. Nature Aging. 2020;1(1):114-23. 441 Park JC, Han SH, Yi D, Byun MS, Lee JH, Jang S, et al. Plasma tau/amyloid-beta1-42 442 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. Brain. 443 2019;142(3):771-86. 444 Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 445 increases with Alzheimer's disease clinical severity and is associated with tau- and 446 amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989-97. 447 Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau 448 isoforms track CNS change in Alzheimer's disease. J Exp Med. 449 2020;217(11):e20200861. 450 10. Albani D, Marizzoni M, Ferrari C, Fusco F, Boeri L, Raimondi I, et al. Plasma Aβ42 as a 451 Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild 452 Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. J Alzheimers Dis. 453 2019;69(1):37-48. 454 11. Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels 455 in Alzheimer's disease. Neurosci Lett. 2017;650:60-4. 456 12. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma

457 Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA 458 Neurol. 2017;74(5):557-66. 459 13. Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suarez-Calvet M, 460 et al. Diagnostic performance and prediction of clinical progression of plasma 461 phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry. 462 2021;26(2):429-42. 463 14. Chatterjee P, Goozee K, Sohrabi HR, Shen K, Shah T, Asih PR, et al. Association of 464 Plasma Neurofilament Light Chain with Neocortical Amyloid-beta Load and Cognitive 465 Performance in Cognitively Normal Elderly Participants. J Alzheimers Dis. 466 2018;63(2):479-87. 467 15. Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and 468 cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep. 469 2018;8(1):17368. 470 16. Shi Y, Lu X, Zhang L, Shu H, Gu L, Wang Z, et al. Potential Value of Plasma Amyloid-beta, 471 Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. ACS 472 Chem Neurosci. 2019;10(8):3479-85. 473 17. Lee JJ, Choi Y, Chung S, Yoon DH, Choi SH, Kang SM, et al. Association of Plasma 474 Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of 475 Consortium to Establish a Registry for Alzheimer's Disease in Health Screening 476 Population. Diagnostics (Basel). 2020;10(4):237. 477 18. Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, et al. Plasma 478 Amyloid-beta Biomarker Associated with Cognitive Decline in Preclinical Alzheimer's

- 479 Disease. J Alzheimers Dis. 2020;77(3):1057-65.
- 480 19. Tsai CL, Liang CS, Lee JT, Su MW, Lin CC, Chu HT, et al. Associations between Plasma
- 481 Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnestic Mild
- 482 Cognitive Impairment: A Cross-Sectional and Longitudinal Study. J Clin Med.
- 483 2019;8(11):1893.
- 20. Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels
- in Alzheimer's disease. Neurosci Lett. 2017;650:60-4.
- 486 21. Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD, et al. A
- 487 longitudinal examination of plasma neurofilament light and total tau for the clinical
- detection and monitoring of Alzheimer's disease. Neurobiol Aging. 2020;94:60-70.
- 489 22. Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al.
- 490 Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly
- 491 associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12(1):118.
- 492 23. Dage JL, Wennberg AMV, Airey DC, Hagen CE, Knopman DS, Machulda MM, et al.
- Levels of tau protein in plasma are associated with neurodegeneration and cognitive
- function in a population-based elderly cohort. Alzheimers Dement. 2016;12(12):1226-34.
- 495 24. Ding D, Zhao Q, Guo Q, Meng H, Wang B, Yu P, et al. The Shanghai Aging Study: study
- 496 design, baseline characteristics, and prevalence of dementia. Neuroepidemiology.
- 497 2014;43(2):114-22.
- 498 25. Luo J, Zhu G, Zhao Q, Guo Q, Meng H, Hong Z, et al. Prevalence and risk factors of poor
- sleep quality among Chinese elderly in an urban community: results from the Shanghai
- aging study. PLoS One. 2013;8(11):e81261.

501 26. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG. Genetic analysis of 502 radiation-induced changes in human gene expression. Nature. 2009;459(7246):587-91. 503 27. Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, et al. The prevalence of 504 dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and 505 education. Ann Neurol. 1990;27(4):428-37. 506 28. Chen KL, Xu Y, Chu AQ, Ding D, Liang XN, Nasreddine ZS, et al. Validation of the 507 Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive 508 Impairment. J Am Geriatr Soc. 2016;64(12):e285-e90. 509 29. Huang L, Chen KL, Lin BY, Tang L, Zhao QH, Lv YR, et al. Chinese version of Montreal 510 Cognitive Assessment Basic for discrimination among different severities of Alzheimer's 511 disease. Neuropsychiatr Dis Treat. 2018;14:2133-40. 512 30. Huang YY, Qian SX, Guan QB, Chen KL, Zhao QH, Lu JH, et al. Comparative study of 513 two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive 514 Impairment. Appl Neuropsychol Adult. 2019:1-6. 515 31. Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, et al. Prevalence of mild cognitive 516 impairment in an urban community in China: a cross-sectional analysis of the Shanghai 517 Aging Study. Alzheimers Dement. 2015;11(3):300-9 e2. 518 32. Zhao Q, Lv Y, Zhou Y, Hong Z, Guo Q. Short-term delayed recall of auditory verbal 519 learning test is equivalent to long-term delayed recall for identifying amnestic mild 520 cognitive impairment. PLoS One. 2012;7(12):e51157. 521 33. Guo Q, Zhao Q, Chen M, Ding D, Hong Z. A comparison study of mild cognitive 522 impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord.

523 2009;23(3):253-9

- 524 34. Zhou B, Zhao Q, Kojima S, Ding D, Higashide S, Nagai Y, et al. One-year Outcome of
- 525 Shanghai Mild Cognitive Impairment Cohort Study. Curr Alzheimer Res.
- 526 2019;16(2):156-65.
- 527 35. Weixiong S, Chuanzhen LV, Yimin S, Lv CZ, Guo QH. Boston naming test in Chinese
- 528 elderly: patient with mild cognitive impairment and Alzheimer's dementia. Chinese Mental
- 529 Health J. 2006;20:81-84.
- 530 36. Lu J, Guo Q, Hong Z, Shi W, Lu C. Trail making test used by Chinese elderly patients with
- 531 mild cognitive impairment and mild Alzheimer's dementia. Chinese J Clin Psychol.
- 532 2006;14:118–21.
- 533 37. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules.
- 534 Neurology. 1993;43(11):2412-4.
- 535 38. Lim WS, Chong MS, Sahadevan S. Utility of the clinical dementia rating in Asian
- 536 populations. Clin Med Res. 2007;5(1):61-70.
- 537 39. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders,
- ed 4. Washington, American Psychiatric Association, 1994, p. 143–147.
- 539 40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical
- 540 diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the
- 541 auspices of Department of Health and Human Services Task Force on Alzheimer's
- 542 Disease. Neurology. 1984;34(7):939-44.
- 543 41. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med.
- 544 2004;256(3):183-94.

- 545 42. Petersen RC. Clinical practice. Mild cognitive impairment. New Engl J Med.
- 546 2011;364(23):2227-34.
- 547 43. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E
- and donepezil for the treatment of mild cognitive impairment. New Engl J Med.
- 549 2005;352(23):2379-88.
- 44. IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY:
- 551 IBM Corp.
- 552 45. R Core Team (2020). R: A language and environment for statistical computing. R
- 553 Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
- 554 46. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament
- 555 light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry.
- 556 2019;90(8):870-81.
- 557 47. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β
- 558 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a
- prospective cohort study. The Lancet Neurology. 2013;12(4):357-67.
- 560 48. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H. Correlation between cognitive
- impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's
- 562 disease. J Alzheimers Dis. 2010;22(3):971-80.
- 563 49. Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al.
- 564 Amyloid beta concentrations and stable isotope labeling kinetics of human plasma
- specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841-9.
- 566 50. Busche MA, Hyman BT. Synergy between amyloid-beta and tau in Alzheimer's disease.

567	Nat Neurosci. 2020;23(10):1183-93.
568	51. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA
569	Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers
570	Dement. 2018;14(4):535-62.

Table 1. Demographic characteristics and the neuropsychological assessments among study participants

		Clinical diagnosis				med		_
		NC	aMCI-s	aMCI-m	Mild AD	Mod <mark>ই</mark> ট্র	Severe AD	
	Total	CDR = 0	CDR = 0.5	CDR = 0.5	CDR = 1	CDR 🚅	CDR = 3	
Demographic characteristics	(N = 451)	(N = 131)	(N = 39)	(N = 113)	(N = 67)	$(N = \frac{5}{6} \frac{3}{3})$	(N = 38)	P value
Gender, female, n (%)	260 (57.6)	82 (62.6)	14 (35.9)	69 (61.1)	31 (46.3)	$38 \ (60.3)$	26 (68.4)	0.011
Age, y, mean (SD)	68.6 (8.8)	69.2 (7.1)	69.6 (9.3)	70.0 (8.0)	67.7 (9.7)	69.1 (19).8)	62.3 (8.2)	< 0.001
Education years, mean (SD)	10.3 (4.1)	11.8 (2.9)	13.6 (3.6)	10.2 (3.6)	10.3 (3.6)	8.4 (4)	5.6 (4.0)	< 0.001
Smoking, n (%)	79 (17.5)	17 (13.0)	5 (12.8)	23 (20.4)	15 (22.4)	12 (1 % 💩)	7 (18.4)	0.529
Alcohol consumption, n (%)	77 (17.1)	19 (14.5)	4 (10.3)	21 (18.6)	18 (26.9)	12 (2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	3 (7.9)	0.139
Hypertension, n (%)	168 (37.3)	53 (40.5)	17 (43.6)	44 (38.9)	23 (34.3)	22 📆 🛞)	9 (23.7)	0.461
Diabetes mellitus, n (%)	68 (15.1)	19 (14.5)	7 (17.9)	19 (16.8)	8 (11.9)	10 🖁 💆 🖲	5 (13.2)	0.933
APOE ε4 positive, n (%)	161 (35.7)	13 (9.9)	12 (30.8)	48 (42.5)	30 (44.8)	36 (1) (1) (3) (3) (3) (3) (3) (3) (3) (3) (3) (3	22 (57.9)	< 0.001
Neuropsychological tests						5.21; thor/ unc		
MMSE score, mean (SD)	23.3 (6.7)	29.0 (1.3)	27.7 (1.7)	25.8 (1.9)	21.9 (1.4)	15. 🖫 📆 📆)	7.4 (2.6)	< 0.001
Memory*, median [Q1, Q3]	-0.07 [-1.18, 0.72]	0.87 [0.56, 1.50]	0.16 [-0.23, 0.72]	-0.23 [-0.71, 0.72]	-0.71 [-1.18, -0.23]	-1.[8] -1.18, -0.82]	-1.18 [-1.18, -1.18]	< 0.001
Execution function*, median [Q1, Q3]	0.43 [-1.25, 0.43]	0.43 [0.43, 0.43]	0.43 [0.43, 1.49]	-0.41 [-1.25, 1.28]	0.43 [-1.25, 0.43]	-1.25 [] .25, -0.41]	-1.25 [-1.25, -1.25]	< 0.001
Attention*, median [Q1, Q3]	0.43 [-0.39, 0.83]	0.83 [0.67, 0.83]	0.69 [0.40, 0.83]	0.43 [-0.21, 0.83]	-0.36 [-0.78, 0.43]	-1.46 च्रु छैं .99, -0.39]	-2.01 [-2.42, -2.01]	< 0.001
Language*, median [Q1, Q3]	0.58 [-0.27, 0.72]	0.72 [0.58, 0.72]	0.58 [0.16, 0.72]	-0.27 [-0.66, 0.72]	-0.27 [-1.16, 0.72]	-0.27 ਹੈ ਹੈ .26, 0.72]	-1.26 [-2.25, -0.27]	< 0.001
Visuospatial function*, median [Q1, Q3]	0.31 [-0.63, 0.93]	0.93 [0.62, 0.93]	0.76 [0.31, 0.93]	0.15 [-0.32, 0.62]	-0.63 [-1.25, -0.005]	-1.253 A.87, -0.32]	-1.87 [-2.18, -1.02]	< 0.001

Visuospatial function*, median [Q1, Q3] 0.31 [-0.63, 0.93] 0.93 [0.62, 0.93] 0.76 [0.31, 0.93] 0.15 [-0.32, 0.62] -0.63 [-1.25, -0.005] -1.25 [-0.32] 8.7, -0.32] -1.87 [-2.18, -1.02] <0.001

Note: * Z score transformed. NC, normal cognition; aMCI-s, amnestic mild cognitive impairment-single domain; aMCI-m, amnestic mild cognitive impairment-multiple and cognitive impairment-multiple and cognitive impairment and cognit

Figure 1. Plasma biomarkers in participants with different clinical cognitive status.

Note: The ANOVA and the post hoc Tukey test were used for comparison of plasma $A\beta_{1-40}$ & $A\beta_{1-42}$ in six groups, while Welch test and the post hoc Games-Howell test were used to compare the plasma $A\beta_{1-42}/A\beta_{1-40}$, t-tau, NfL, p-tau181 among six groups. Six extreme values were not shown in panel E, but they were included in the statistical analyses. *P* values are presented with asterisks: * P < 0.05, ** P < 0.01, *** P < 0.001, *** P < 0.0001. NC, normal cognition; aMCI-s, amnestic mild cognitive impairment-single domain; aMCI-m, amnestic mild cognitive impairment-multiple domains; AD, Alzheimer's disease; CDR, Clinical Dementia Rating Scale; $A\beta$, amyloid-beta protein; t-tau, total tau; NfL, neurofilament protein light chain; p-tau181, tau phosphorylated at threonine 181.

Figure 2. Correlations between plasma biomarkers and cognitive domains.

Note: The plasma biomarkers concentrations were log transformed. The Pearson correlation coefficients (*r*) were adjusted for age, gender, education year, and APOE. Aβ, amyloid-beta protein; t-tau, total tau; NfL, neurofilament protein light chain; p-tau181, tau phosphorylated at threonine 181.

Table 2. Correlations between plasma biomarkers and global & domain-specific cognition in participants with different AD stages

	Global (MMSE)								Men	nory	edR	Attention						
	CDR = 0		CDR = 0.5		CDR ≥ 1		CDR = 0		CDR = 0.5		CD <mark>≹</mark> Ž 1	CDR = 0		CDR = 0.5		CDR	$R \ge 1$	
Biomarkers	r	P	r	P	r	P	r	P	r	P	$r \stackrel{Sign}{\underset{ap}{pr}} P$	r	P	r	P	r	P	
Plasma Aβ ₁₋₄₀	-0.105	0.256	0.097	0.240	-0.032	0.681	-0.088	0.350	0.048	0.574	0.083 💆 0.331	-0.094	0.311	-0.052	0.542	-0.060	0.480	
Plasma $A\beta_{1-42}$	-0.086	0.350	-0.109	0.188	0.067	0.394	-0.023	0.805	0.148	0.080	$0.184 \stackrel{\square}{=} 0.030$	-0.169	0.068	-0.020	0.814	0.038	0.659	
Plasma $A\beta_{1-42}/A\beta_{1-40}$	-0.023	0.804	-0.209	0.011	0.156	0.046	0.028	0.767	0.127	0.135	0.112	-0.122	0.190	-0.013	0.877	0.187	0.028	
Plasma t-tau	-0.008	0.933	-0.108	0.193	-0.132	0.092	-0.182	0.051	-0.151	0.074	-0.063	-0.119	0.203	-0.079	0.353	-0.042	0.622	
Plasma NfL	-0.168	0.067	-0.052	0.530	-0.129	0.104	0.048	0.610	-0.083	0.330	-0.158	-0.053	0.568	-0.026	0.762	0.030	0.732	
Plasma p-tau181	-0.011	0.907	-0.076	0.360	-0.295	< 0.001	-0.025	0.793	-0.167	0.048	$-0.17\overline{2}_{2}$	0.068	0.467	0.005	0.949	-0.184	0.031	

		Visuospatial function							Language						Executive function					
	CDR = 0		CDR = 0.5		CDR ≥ 1		CDR = 0		CDR = 0.5		C ₽ R ≥ 1	CDR = 0		CDR = 0.5		CDR	R ≥ 1			
Biomarkers	r	P	r	P	r	P	r	P	r	P	r und P	r	P	r	P	r	P			
Plasma Aβ ₁₋₄₀	-0.108	0.250	-0.024	0.785	0.099	0.280	-0.152	0.103	-0.093	0.272	-0.04 0.641	-0.011	0.908	0.041	0.631	-0.002	0.984			
Plasma $A\beta_{1-42}$	-0.004	0.963	-0.149	0.089	0.114	0.217	-0.083	0.375	-0.127	0.133	-0.01 $\frac{1}{8}$ $\frac{1}{5}$ $\frac{1}{5}$ 0.904	-0.074	0.442	-0.117	0.169	0.062	0.471			
Plasma $A\beta_{1-42}/A\beta_{1-40}$	0.092	0.327	-0.131	0.137	0.049	0.593	0.090	0.337	-0.098	0.249	0.03 و المَّا يَّقِينَ الْمُعَامِّينَ الْمُعَامِّينِ الْمُعَامِينِ الْمُعَامِّينِ الْمُعَامِّينِ الْمُعَامِّينِ 1.673 ما	-0.092	0.339	-0.197	0.021	0.085	0.322			
Plasma t-tau	0.048	0.607	0.117	0.183	-0.102	0.270	-0.007	0.943	-0.058	0.492	-0.025 $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{5}$ $\frac{1}{5}$ 0.775	0.003	0.973	0.017	0.843	-0.032	0.711			
Plasma NfL	-0.047	0.616	-0.174	0.045	0.042	0.652	-0.147	0.115	0.038	0.654	0.0079900.932	0.056	0.558	0.127	0.136	-0.171	0.048			
Plasma p-tau181	0.079	0.398	-0.044	0.616	-0.066	0.479	-0.025	0.793	0.071	0.405	$0.067 = \frac{100}{2} = \frac{100}{100} = 0.438$	0.006	0.948	0.133	0.120	-0.060	0.489			

Note: The plasma biomarkers concentrations were log transformed. The Pearson correlation coefficients (r) were adjusted for age, gender, education year, and APOE. In numbers indicate P < 0.05. Note: The plasma biomarkers concentrations were log transformed. The Pearson correlation coefficients (r) were adjusted for age, gender, education year, and APOE. Box an



